Today on Drug Discovery & Development
Pfizer highlights COVID-19 and flu vaccine strategy in Q2 earnings call
With vaccines generating a significant portion of Pfizer’s (NYSE:PFE) revenue in the first six months of 2021, the company shed light on its vaccine plans in its most recent quarterly earnings call. While the company recently won FDA approval for its potential blockbuster pneumococcal 20-valent vaccine, its mRNA vaccine strategy understandably took center stage during…
Satsuma launches Phase 3 trial for acute migraine drug
Satsuma Pharmaceuticals (NSDQ:STSA) has announced that it has enrolled the first patient in its SUMMIT Phase 3 efficacy trial of STS101, a drug-device product that is a potential acute treatment of migraine. STS101 is a nasal powder containing dihydroergotamine (DHE), an analgesic already available to treat migraines and cluster headaches. In fact, migraine patients have…
Drug Discovery and Development See More >
FDA approves Merck’s Keytruda to treat certain types of breast cancer
Merck (NYSE:MRK) announced today that it received FDA approval for Keytruda for treating high-risk, early-stage, triple-negative breast cancer (TNBC). Kenilworth, N.J.-based Merck’s Keytruda anti-PD-1 therapy received approval for use in combination with chemotherapy as neoadjuvant treatment, then continued as a single agent as adjuvant treatment after surgery, according to a news release. Approval was based…
Sponsored Content See More >
Resolving binding kinetics on a microplate readerWith a better understanding of the causes and mechanisms behind diseases arises a need for new treatment options and drugs…
Noble expands its services for its clients into Human FactorsHuman Factors + (HF+) is a natural extension of Noble’s deep understanding of the patient experience relative to self-administering drug…
Micro 3D Printing Advances Biomarker DetectionResearchers in China have used Projection Micro Stereolithography (PµSL) to improve the fabrication of micropillar array electrodes (µAEs) for the…
Genomics/Proteomics See More >
DNA Script launches a benchtop DNA printer
DNA Script announced the commercial launch of its Syntax platform with the Syntax system, a benchtop nucleic acid printer. South San Francisco, Calif.-based DNA Script designed its Syntax system, a fully integrated, automated printer powered by enzymatic DNA synthesis (EDS) technology, to synthesize 96 DNA oligos in parallel, comprised of up to 60 nucleotides in…
Infectious Disease See More >
Pfizer highlights COVID-19 and flu vaccine strategy in Q2 earnings call
With vaccines generating a significant portion of Pfizer’s (NYSE:PFE) revenue in the first six months of 2021, the company shed light on its vaccine plans in its most recent quarterly earnings call. While the company recently won FDA approval for its potential blockbuster pneumococcal 20-valent vaccine, its mRNA vaccine strategy understandably took center stage during…
Preprint shows strong but fading efficacy of Pfizer vaccine at six months
FDA approves GSK’s Shingrix to prevent shingles in immunocompromised adults
AstraZeneca, Pfizer Moderna vaccines fare well against Beta, Gamma and Delta variants in study
Man experiences facial palsy twice after receiving both COVID-19 vaccine doses
Oncology See More >
FDA grants orphan drug designation to investigational Novartis drug NIS793
FDA has granted orphan drug designation for Novartis’s (SWX:NOVN) NIS793, an anti-TGF-β IgG2 monoclonal antibody. Specifically, the designation covers the use of NIS793 in conjunction with standard-of-care chemotherapy to treat pancreatic cancer. NIS793 has been the subject of eight clinical trials for indications ranging from solid tumors to myelofibrosis. NIS793 would be a first-in-class antibody specific…
